Engitix announces $25 million series extension financing to advance ECM-targeted therapeutics

Engitix Ltd, a biotech company targeting the extracellular matrix (ECM) to develop transformative therapies for cancer and fibrosis, today announced the closing of a $25 million Series A extension financing, by Netherton Investments, a fund investing on behalf of Mike Platt, the co-founder and Managing Director of BlueCrest Capital Management.

Proceeds will be used to continue preclinical development across Engitix’s proprietary ECM-targeted pipeline in solid tumors and fibrosis, and to further expand and apply Engitix’s platform built on one of the largest proprietary ECM datasets in these diseases. Engitix leverages deep, high-resolution ECM data to identify disease-associated signatures and translate them into therapeutics designed to act precisely within diseased tissue microenvironments.

Giuseppe Mazza, CEO and Co-Founder of Engitix, said:

Closing this financing strengthens our ability to translate Engitix’s unique ECM understanding into a growing pipeline of targeted therapeutics. Our platform and dataset position us to accelerate preclinical development across oncology and fibrosis programs and build differentiated, ECM-targeted therapeutics with the potential to meaningfully improve patient outcomes.

Mike Platt, Investor Director, added:

Engitix has developed a compelling strategy at the intersection of data, biology, and drug development. I’m pleased to continue supporting Engitix as it advances its programs in fibrosis and solid tumors.